News & Updates

Show Multimedia Only

Insulin glargine plus lixisenatide improves outcomes in Chinese adults with T2D

17 Dec 2025 by

Treatment with iGlarLixi* resulted in better clinical outcomes than IDegAsp** in Chinese adults with type 2 diabetes (T2D), regardless of age or disease duration at baseline, according to a post hoc analysis of the phase III Soli-D study presented at ATTD-ASIA 2025.

Insulin glargine plus lixisenatide improves outcomes in Chinese adults with T2D

17 Dec 2025

Add-on ON101 cost-effective for DFUs

16 Dec 2025 by

An economic analysis shows the cost-effectiveness of adding ON101 to general wound care (GWC) for the treatment of diabetic foot ulcers (DFUs) in individuals with type 2 diabetes (T2D) in Singapore, with robust results across subgroup and sensitivity analyses.

Add-on ON101 cost-effective for DFUs

16 Dec 2025

Eloralintide looks good for obesity

14 Dec 2025

Treatment with the novel selective amylin receptor agonist eloralintide results in substantial, dose-dependent reductions in bodyweight in adults with obesity, according to a phase II trial.

Eloralintide looks good for obesity

14 Dec 2025

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

13 Dec 2025

Outpatient use of nirmatrelvir/ritonavir lowers the risk of severe COVID-19-related outcomes, regardless of age or vaccination status, in a large, nationally representative cohort study in Taiwan, highlighting the importance of early antiviral treatment in ageing and unvaccinated populations.

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

13 Dec 2025

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

13 Dec 2025

A study presented at IDWeek 2025 demonstrates substantial medication cost savings, shorter hospital stays, reduced treatment duration, and lower rates of progression to severe disease when nirmatrelvir-ritonavir (NMV/r) was added to the acute care formulary for treating elderly patients with mild-to-moderate COVID-19.

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

13 Dec 2025

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

13 Dec 2025

Treatment with nirmatrelvir/ritonavir significantly reduced mortality risk among hospitalized COVID-19 patients compared with the combined molnupiravir and nirmatrelvir/ritonavir regimen, according to a target trial emulation study presented at IDWeek 2025.

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

13 Dec 2025

Bedtime snacking may worsen T1D control in kids

12 Dec 2025

In young children with type 1 diabetes (T1D), bedtime snacking appears to result in higher nocturnal glucose values and reduced time in range (TIR), without decreasing the frequency of hypoglycaemia, according to a randomized controlled crossover trial.

Bedtime snacking may worsen T1D control in kids

12 Dec 2025

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025 by

Treatment with semaglutide appears to improve glycaemic control and weight outcomes in patients with schizophrenia receiving second-generation antipsychotics, as shown in a study.

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025

X-linked hypophosphataemia: Multidisciplinary care needed, targeted therapy effectively normalizes phosphate homeostasis

11 Dec 2025

Management of X-linked hypophosphataemia (XLH) has evolved in the past few years following the availability of burosumab, a fully humanized monoclonal antibody targeting circulating fibroblast growth factor 23 (FGF23), which has changed the landscape of XLH management, a panel of experts who spoke at EDM HK 2025 concurred.

X-linked hypophosphataemia: Multidisciplinary care needed, targeted therapy effectively normalizes phosphate homeostasis

11 Dec 2025

Does palmitoleic acid supplementation reduce hs-CRP in adults?

10 Dec 2025

Supplementation with palmitoleic acid (POA) 500 or 1,000 mg/day does not appear to substantially reduce high-sensitivity C-reactive protein (hs-CRP) or change other biomarkers in adults relative to placebo, reports a study.

Does palmitoleic acid supplementation reduce hs-CRP in adults?

10 Dec 2025

News & Updates

Showing Endocrinology articles

Showing

Specialty:

Insulin glargine plus lixisenatide improves outcomes in Chinese adults with T2D

Insulin glargine plus lixisenatide improves outcomes in Chinese adults with T2D

Add-on ON101 cost-effective for DFUs

Add-on ON101 cost-effective for DFUs

Eloralintide looks good for obesity

Eloralintide looks good for obesity

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

Bedtime snacking may worsen T1D control in kids

Bedtime snacking may worsen T1D control in kids

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

X-linked hypophosphataemia: Multidisciplinary care needed, targeted therapy effectively normalizes phosphate homeostasis

X-linked hypophosphataemia: Multidisciplinary care needed, targeted therapy effectively normalizes phosphate homeostasis

Does palmitoleic acid supplementation reduce hs-CRP in adults?

Does palmitoleic acid supplementation reduce hs-CRP in adults?